Search for: "Pharmaceutical Associates, Inc."
Results 1 - 20
of 1,901
Sorted by Relevance
|
Sort by Date
12 Aug 2010, 9:57 pm
By Andrew Williams -- Last week, in King Pharmaceuticals, Inc. v. [read post]
27 Mar 2019, 7:15 am
Regeneron Pharmaceuticals Inc. is seeking a patent attorney at the Associate Director level to assist with the development of strategies for expanding Regeneron’s intellectual property protection around key molecules, platforms and other technologies to ensure Regeneron’s long-term competitive advantage.The patent attorney will also provide IP transactional support in partnership with colleagues and clients in R&D, clinical, regulatory, legal, business and… [read post]
15 Dec 2010, 9:59 pm
Patent and Trademark Office ("Myriad") case, Alnylam Pharmaceuticals, Inc. supports reversal of the District Court's decision and asks the Federal Circuit "to provide clear guidance on patent-eligibility to remove the unnecessary cloud cast by the decision below. [read post]
3 Jul 2007, 10:55 pm
Medicines Australia (formerly the Australian Pharmaceutical Manufacturers' Association Inc) has a Code of Conduct which sets the standards for the ethical marketing and promotion of prescription pharmaceutical products in Australia. [read post]
9 Jul 2018, 8:51 pm
Patent and Trademark Office, the Office addresses a recent decision by the Federal Circuit in Vanda Pharmaceuticals Inc. v. [read post]
27 Mar 2019, 7:15 am
Regeneron Pharmaceuticals Inc. is seeking a patent attorney at the Associate Director level to assist with the development of strategies for expanding Regeneron’s intellectual property protection around key molecules, platforms and other technologies to ensure Regeneron’s long-term competitive advantage.The patent attorney will also provide IP transactional support in partnership with colleagues and clients in R&D, clinical, regulatory, legal, business and… [read post]
15 Nov 2018, 9:28 am
New Jersey’s Attorney General filed a lawsuit Tuesday against Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, for misleading patients and prescribers about the addictive risks associated with the use of its drugs. [read post]
1 Jul 2019, 4:15 am
Regeneron Pharmaceuticals Inc. is seeking a patent attorney at the Associate Director level to assist with the development of strategies for expanding Regeneron’s intellectual property protection around key molecules, platforms and other technologies to ensure Regeneron’s long-term competitive advantage. [read post]
5 Dec 2020, 12:44 pm
According to a press release on May 9, 2019, C3J Therapeutics, Inc. and AmpliPhi Biosciences Corporation merged into a new combined company, known as Armata Pharmaceuticals, Inc. [read post]
15 Apr 2017, 8:47 pm
Jonas Anderson, American University Washington College of Law, with a panel consisting of Jennifer Thomas of Hyman, Phelps & McNamara, PC, representing Pharmaceutical Care Management Association, et al. on amicus brief; Donald Ware of Foley Hoag... [read post]
27 Aug 2020, 2:06 pm
If you have losses from investing in Fennec Pharmaceuticals Inc. [read post]
24 Sep 2019, 7:51 am
Inc as co managers for the offering. [read post]
8 Nov 2017, 7:26 am
Actavis, Inc., et al, No. [read post]
8 Feb 2012, 7:19 am
Cadence Pharmaceuticals, Inc. [read post]
1 Jul 2013, 10:16 am
Last year, the Court held in PLIVA, Inc. v. [read post]
7 Aug 2013, 11:00 pm
In Teva Pharmaceuticals USA, Inc. v. [read post]
4 Jun 2013, 1:40 pm
On Friday, May 24, 2013, ISTA Pharmaceuticals, Inc., a pharmaceutical company recently acquired by Bausch & Lomb, Inc., pled guilty to violating the Federal Anti-Kickback Statute and the Food, Drug and Cosmetic Act (FDCA). [read post]
10 Mar 2013, 9:59 pm
Searle LLC; Pfizer Asia Pacific PTE, LTD.; • Defendants: Lupin Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Watson Laboratories, Inc.; Apotex Inc.; Apotex Corp. [read post]
1 Dec 2021, 1:29 pm
Pfizer, Inc. [read post]
1 Jul 2019, 4:15 am
Regeneron Pharmaceuticals Inc. is seeking a patent attorney at the Associate Director level to assist with the development of strategies for expanding Regeneron’s intellectual property protection around key molecules, platforms and other technologies to ensure Regeneron’s long-term competitive advantage. [read post]
